Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

Abstract Background Dermatomyositis is an idiopathic inflammatory myopathy characterised by rashes and progressive muscle weakness. The recent ProDERM (Progress in DERMatomyositis) study is the first large randomised, placebo-controlled trial to establish the efficacy and safety of intravenous immun...

Full description

Bibliographic Details
Main Authors: Rohit Aggarwal, Joachim Schessl, Christina Charles-Schoeman, Zsuzsanna Bata-Csörgő, Mazen M. Dimachkie, Zoltan Griger, Sergey Moiseev, Chester V. Oddis, Elena Schiopu, Jiri Vencovský, Irene Beckmann, Elisabeth Clodi, Todd Levine, the ProDERM investigators
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Arthritis Research & Therapy
Subjects:
Dermatomyositis
Intravenous immunoglobulin
Myositis
Safety
Tolerability
Online Access:https://doi.org/10.1186/s13075-023-03232-2

Internet

https://doi.org/10.1186/s13075-023-03232-2

Similar Items